Monitoring of chronic Immune Thrombocytopenia (ITP) treated with thrombopoietin receptor (TPO-R) agonists in France FRESH-PEF3133-en Christel LECLERC-ZWIRN Monitoring of chronic Immune Thrombocytopenia (ITP) treated with thrombopoietin receptor (TPO-R) agonists in France SATURNE FRESH-PEF3133-en 3133 FRESH-PEF3133 Christel LECLERC-ZWIRN GLAXOSMITHKLINE (FRANCE) Epidemiology France Portal (PEF) GLAXOSMITHKLINE (FRANCE) null Christel;LECLERC-ZWIRN Hematology Clinical immunology Thrombotic thrombocytopenic purpura Describing the profile of patients with chronic ITP treated with TPO-R agonists and the clinical course of their disease over 2 years null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Each participating physician is to include in a cross-sectional registry the first patients who are managed for their ITP persistent or chronic. Each physician could fill information about 15 patients maximum. Among the maximum of 15 patients included in the cross-sectional registry, each participating physician is to include in the cohort, in a consecutive manner, the first 3 to 8 patients with chronic ITP at TPO-R agonist treatment initiation in compliance with the inclusion criteria Clinical data Participant-reported health data Biological data Socio-demographic data Health event/morbidity Health event/mortality Health care consumption and services Quality of life/health perception Probability: Stratified Through organizations (health services or institutions schools businesses etc.) [500-1000[ individuals Self-administered questionnaire Interview with the participant (including clinical) Observational Study Observational Study 500 Unknown Restricted access Access on specific project only